Citius Pharmaceuticals stock hits 52-week low at $0.92

In a challenging year for Citius Pharmaceuticals Inc (NASDAQ:CTXR)., the company’s stock has tumbled to a 52-week low, touching down at $0.92. According to InvestingPro data, the company’s overall financial health score is rated as WEAK, with analysts setting price targets between $4 and $9. This latest price level reflects a stark downturn in the company’s market valuation, with Citius experiencing a precipitous 1-year change of -94.73%. Investors have watched with concern as the stock struggled to find its footing amidst a series of market challenges, ultimately leading to this new low point. The significant drop in stock value over the past year has placed Citius Pharmaceuticals at the center of discussions about market volatility and the pressures facing the pharmaceutical industry. InvestingPro analysis indicates the stock is currently undervalued, though concerning metrics include a current ratio of 0.41, suggesting potential liquidity challenges. For deeper insights into the company’s prospects, InvestingPro subscribers can access 11 additional key tips about CTXR’s financial position.

In other recent news, Citius Pharmaceuticals reported its fiscal first-quarter results, ending on December 31, 2024. The company received a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Lymphir from the Centers for Medicare and Medicaid Services, marking a significant step towards its commercialization. Citius anticipates launching Lymphir in the first half of 2025. Additionally, Citius announced positive top-line results from its pivotal Phase 3 clinical trial for Mino-Lok, an antibiotic lock solution, which positions the company to potentially commercialize two therapies by the first half of 2026. H.C. Wainwright analysts revised their price target for Citius Pharmaceuticals, lowering it from $100 to $4, but maintained a Buy rating on the stock. The revision accounts for recent financial adjustments and a reverse stock split. Analysts at H.C. Wainwright have expressed confidence in Citius’s progress, suggesting that the market may not fully appreciate the company’s prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.